187 related articles for article (PubMed ID: 12566894)
1. Comparison of 1-hour and 3-hours paclitaxel infusion pharmacokinetics: results from a randomized trial.
Mross K; Häring B; Holländer N; Mielke S; Behringer D; Massing U; Unger C
Onkologie; 2002 Dec; 25(6):503-8. PubMed ID: 12566894
[TBL] [Abstract][Full Text] [Related]
2. PAC fixed dose: pharmacokinetics of a 1-hour paclitaxel infusion and comparison to BSA-normalized drug dosing.
Mross K; Holländer N; Frost A; Unger C; Ziroli V; Massing U
Onkologie; 2006 Oct; 29(10):444-50. PubMed ID: 17028453
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics of a 1-h paclitaxel infusion.
Mross K; Holländer N; Hauns B; Schumacher M; Maier-Lenz H
Cancer Chemother Pharmacol; 2000; 45(6):463-70. PubMed ID: 10854133
[TBL] [Abstract][Full Text] [Related]
4. Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions.
Gelderblom H; Mross K; ten Tije AJ; Behringer D; Mielke S; van Zomeren DM; Verweij J; Sparreboom A
J Clin Oncol; 2002 Jan; 20(2):574-81. PubMed ID: 11786588
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of a new taxoid, RPR 109881A, given as a 1-hour intravenous infusion in patients with advanced solid tumors.
Kurata T; Shimada Y; Tamura T; Yamamoto N; Hyodo I; Saeki T; Takashima S; Fujiwara K; Wakasugi H; Kashimura M
J Clin Oncol; 2000 Sep; 18(17):3164-71. PubMed ID: 10963645
[TBL] [Abstract][Full Text] [Related]
6. Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763.
Miller AA; Rosner GL; Egorin MJ; Hollis D; Lichtman SM; Ratain MJ
Clin Cancer Res; 2004 Dec; 10(24):8325-31. PubMed ID: 15623609
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion.
Ohtsu T; Sasaki Y; Tamura T; Miyata Y; Nakanomyo H; Nishiwaki Y; Saijo N
Clin Cancer Res; 1995 Jun; 1(6):599-606. PubMed ID: 9816021
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients.
Huizing MT; Keung AC; Rosing H; van der Kuij V; ten Bokkel Huinink WW; Mandjes IM; Dubbelman AC; Pinedo HM; Beijnen JH
J Clin Oncol; 1993 Nov; 11(11):2127-35. PubMed ID: 7901342
[TBL] [Abstract][Full Text] [Related]
9. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.
Lum BL; Kaubisch S; Fisher GA; Brown BW; Sikic BI
Cancer Chemother Pharmacol; 2000; 45(4):305-11. PubMed ID: 10755319
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmacodynamic analysis of neutropenia following nab-paclitaxel administration in Japanese patients with metastatic solid cancer.
Tsushima T; Kasai H; Tanigawara Y
Cancer Chemother Pharmacol; 2020 Oct; 86(4):487-495. PubMed ID: 32930844
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion.
Panday VR; ten Bokkel Huinink WW; Vermorken JB; Rosing H; Koopman FJ; Swart M; Schellens JH; Beijnen JH
Pharmacol Res; 1999 Jul; 40(1):67-74. PubMed ID: 10378993
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study.
Joerger M; Kraff S; Huitema AD; Feiss G; Moritz B; Schellens JH; Beijnen JH; Jaehde U
Clin Pharmacokinet; 2012 Sep; 51(9):607-17. PubMed ID: 22804749
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities.
Tamura T; Sasaki Y; Nishiwaki Y; Saijo N
Jpn J Cancer Res; 1995 Dec; 86(12):1203-9. PubMed ID: 8636011
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial.
Huizing MT; Vermorken JB; Rosing H; ten Bokkel Huinink WW; Mandjes I; Pinedo HM; Beijnen JH
Ann Oncol; 1995 Sep; 6(7):699-704. PubMed ID: 8664192
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH.
Mross K; Hüttmann A; Herbst K; Hanauske AR; Schilling T; Manegold C; Burk K; Hossfeld DK
Cancer Chemother Pharmacol; 1996; 38(3):217-24. PubMed ID: 8646795
[TBL] [Abstract][Full Text] [Related]
17. Influence of the cyto-protective agent amifostine on the pharmacokinetics of low-dose Paclitaxel.
Juan O; Rocher A; Sánchez A; Sánchez JJ; Alberola V
Chemotherapy; 2005 Jul; 51(4):200-5. PubMed ID: 15985759
[TBL] [Abstract][Full Text] [Related]
18. Influence of the interval between the administration of doxorubicin and paclitaxel on the pharmacokinetics of these drugs in patients with locally advanced breast cancer.
Moreira A; Lobato R; Morais J; Silva S; Ribeiro J; Figueira A; Vale D; Sousa C; Araújo F; Fernandes A; Oliveira J; Passos-Coelho JL
Cancer Chemother Pharmacol; 2001 Oct; 48(4):333-7. PubMed ID: 11710635
[TBL] [Abstract][Full Text] [Related]
19. Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study.
Borgå O; Henriksson R; Bjermo H; Lilienberg E; Heldring N; Loman N
Adv Ther; 2019 May; 36(5):1150-1163. PubMed ID: 30879251
[TBL] [Abstract][Full Text] [Related]
20. Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat.
Liu J; Kraut EH; Balcerzak S; Grever M; D'Ambrosio S; Chan KK
Cancer Chemother Pharmacol; 2002 Dec; 50(6):445-53. PubMed ID: 12451470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]